GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Q4 2024 Earnings Call Transcript February 5, 2025 Operator: Good morning, and welcome to the Boston Scientific Fourth Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is ...

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024 ...

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Factors contributing to the ramifications of this disease as it stands include the socio-economic: overweight and obesity ...

Spinal Cord Stimulators Market. The global spinal cord stimulators market is on an accelerated growth path, projected to ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.65 per share, indicating an increase of 18.2% compared to the year-ago period. Analysts forecast ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations while engineers refine cooling techniques, improve battery resilience, and ...